NEW YORK (
CHANGE IN RATINGS
(AIR) was downgraded to Hold at TheStreet Ratings.
(ACM) was downgraded at Bank of America/Merrill Lynch to Underperform. $20 price target. Company lacks near-term catalysts and is a potential value trap, BofA/Merrill said.
(COF - Get Report) was upgraded at Argus from Sell to Hold. Valuation call.
was upgraded from Neutral to Outperform at Robert Baird. Valuation call, based on a $76 price target, Baird said.
was upgraded at Morgan Stanley from Equal-Weight to Overweight. $65 price target. Lower natural gas prices are boosting demand for downstream activity, Morgan Stanley said.
(EA - Get Report)
was upgraded at Needham from Hold to Buy. $22 price target. Strong sales growth can expand margins, Needham said.
was downgraded to Hold at TheStreet Ratings.
was upgraded at Citigroup to Buy from Neutral. $42.50 price target. Compelling valuation and accelerating buyback, Citi said.
was upgraded at Deutsche Bank from Hold to Buy. $12 price target. Housing demand is beginning to recover, Deutsche said.
was downgraded at William Blair to Market Perform. Estimates were also cut, given the company's new guidance, William Blair said.
was initiated with an Equal-weight rating at Morgan Stanley. Valuation call, Morgan Stanley said.
was upgraded at Stifel Nicolaus from Sell to Hold. Valuation call, Stifel Nicolaus said.
was initiated with a Neutral rating at Goldman Sachs. Valuation call, based on a $24 price target, Goldman said.
was downgraded at Wells Fargo to Market Perform. Company cut its guidance because of
, Wells Fargo said.
(VRTX - Get Report)
was upgraded at Morgan Stanley from Underweight to Equal-Weight. $51 price target. Interim cystic fibrosis data were better than expected, Morgan Stanley said.
Vertex Pharmaceuticals was upgraded at Brean Murray. Cystic Fibrosis treatment is performing better than expected in trials. Brean Murray said.
was upgraded at Keybanc from Hold to Buy. $10 price target. Stock has underperformed, but the company is getting aggressive with its cost controls, Keybanc said.
was upgraded at Canaccord Genuity from Hold to Buy. $84 price target. Stock is attractive, following a 20% decline, Canaccord said.